Champions Oncology, Inc. (CSBR) vs Gain Therapeutics, Inc. (GANX)
A side-by-side comparison of Champions Oncology, Inc. and Gain Therapeutics, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
CSBR
Champions Oncology, Inc.
$4.99HealthcareDelayed quote: Oct 6, 2026, 10:34 AM EDT
GANX
Gain Therapeutics, Inc.
$1.71HealthcareDelayed quote: Oct 6, 2026, 10:40 AM EDT
Total return — CSBR vs GANX
growth of $100 · dividends reinvested · last 6yCSBR -62.3% (-15.0%/yr)GANX -84.9% (-27.0%/yr)CSBR compounded faster over this window
CSBR GANX
CSBR vs GANX: by the numbers
- •GANX is the larger company ($73M vs $69M market cap).
- •Both run net losses; GANX's is the smaller (0.00% vs -1.87% net margin).
Metrics side by side
Valuation
| Metric | CSBR | GANX |
|---|---|---|
| Forward P/E | 49.85 | N/A |
| P/S ratio | 1.14 | N/A |
| P/B ratio | 17.79 | 6.44 |
| EV / EBITDA | 260.73 | N/A |
Profitability
| Metric | CSBR | GANX |
|---|---|---|
| Gross margin | 49.30% | 0.00% |
| Operating margin | -1.72% | 0.00% |
| Net margin | -1.87% | 0.00% |
| ROE | -29.15% | -178.06% |
| ROIC | -6.75% | -159.24% |
Growth (annualized)
| Metric | CSBR | GANX |
|---|---|---|
| Revenue CAGR (5Y) | 7.25% | N/A |
| Total return CAGR (5Y) | -13.07% | -25.06% |
Frequently asked
- How have CSBR and GANX total returns compared?
- Over the past 5 years, CSBR delivered -13.07% and GANX delivered -25.06% annualized total return. Past performance doesn't predict future results.
Go deeper
Dig into the metrics
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.